Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07851103) titled 'A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Boehringer Ingelheim
Condition:
Advanced Solid Tumour
Intervention:
Drug: BI 3968621
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 26, 2026
Target Sample Size: 90
Countries of Recruitment:
United States
Belgium
France
Japan
Spain
Belgium
France
Japan
Spain...